Virtu KCG Holdings’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Virtu KCG Holdings’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$110K	Buy	11,314 +3,588	+46%	+$73.3K	﹤0.01%	2386
2017 Q1	$187K	Buy	7,726 +4,302	+126%	+$108K	0.01%	2473
2016 Q4	$110K	Buy	+3,424	New	+$146K	﹤0.01%	2881
2016 Q3	–	Sell	-9,142	Closed	-$388K	–	3730
2016 Q2	$388K	Buy	9,142 +5,418	+145%	+$295K	0.01%	1612
2016 Q1	$245K	Buy	+3,724	New	+$194K	0.01%	1890
2015 Q3	–	Sell	-2,851	Closed	-$277K	–	4108
2015 Q2	$277K	Buy	+2,851	New	+$271K	0.01%	2176
2015 Q1	–	Sell	-1,786	Closed	-$159K	–	4248
2014 Q4	$159K	Buy	+1,786	New	+$130K	﹤0.01%	3021
2014 Q2	–	Sell	-1,983	Closed	-$79K	–	4278
2014 Q1	$79K	Buy	+1,983	New	+$84.9K	﹤0.01%	3261
2013 Q4	–	Sell	-2,337	Closed	-$70K	–	4471
2013 Q3	$70K	Buy	+2,337	New	+$81.8K	﹤0.01%	3451

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Virtu KCG Holdings's MACK Position: Q2 2017 in Review

Virtu KCG Holdings increased its Merrimack Pharmaceuticals, Inc. (MACK) stake by 46% in Q2 2017, buying an estimated $73.3K and bringing the position to 11,314 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

Virtu KCG Holdings first reported a position in MACK in Q3 2013 and has held it in 9 quarters since. The position peaked at $388K in Q2 2016. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

Virtu KCG Holdings held 11,314 shares of Merrimack Pharmaceuticals, Inc. worth $110K as of Q2 2017.
Virtu KCG Holdings bought 3,588 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $73.3K.
Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2386 holding.
Virtu KCG Holdings first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and has held it in 9 quarters since.
Virtu KCG Holdings's Merrimack Pharmaceuticals, Inc. position peaked at $388K in Q2 2016.
119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.